ClinicalTrialsFinder

Sclerosis Clinical Trials in St Louis, Missouri

35 recruitingSt Louis, Missouri

Showing 1–20 of 35 trials

Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 3

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Multiple Sclerosis (MS) Primary Progressive
Zenas BioPharma (USA), LLC705 enrolled12 locationsNCT07067463
Recruiting
Phase 2

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Multiple Sclerosis
ModernaTX, Inc.180 enrolled17 locationsNCT06735248
Recruiting
Phase 1

A Study of AZD0120 in Autoimmune Diseases

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis
AstraZeneca27 enrolled18 locationsNCT07295847
Recruiting
Phase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Relapsing Multiple Sclerosis
Novartis Pharmaceuticals360 enrolled106 locationsNCT06846281
Recruiting

TSC Biosample Repository and Natural History Database

LymphangioleiomyomatosisTuberous Sclerosis
National Tuberous Sclerosis Association5,000 enrolled26 locationsNCT05676099
Recruiting
Phase 3

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled47 locationsNCT05877963
Recruiting
Phase 1

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

Multiple Sclerosis
AstraZeneca24 enrolled19 locationsNCT07224373
Recruiting
Phase 2

Study of COYA 302 for the Treatment of ALS

Amyotrophic Lateral Sclerosis(ALS)
Coya Therapeutics120 enrolled25 locationsNCT07161999
Recruiting

Smoldering Inflammation in MS

Multiple Sclerosis
Washington University School of Medicine25 enrolled1 locationNCT06591429
Recruiting
Phase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis
Sanofi1,600 enrolled384 locationsNCT06141473
Recruiting
Phase 1Phase 2

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis (MS) Primary ProgressiveMultiple Sclerosis (MS) Secondary Progressive+2 more
Tr1X, Inc.39 enrolled2 locationsNCT07477639
Recruiting
Phase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Myasthenia GravisMultiple Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company120 enrolled35 locationsNCT06220201
Recruiting
Not Applicable

Functional Outcomes From Diets in Multiple Sclerosis

Relapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
University of Alabama at Birmingham100 enrolled2 locationsNCT05327322
Recruiting
Phase 2

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

EpilepsyTuberous Sclerosis Complex
Darcy Krueger64 enrolled11 locationsNCT05104983
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

Multiple Sclerosis
Genentech, Inc.60 enrolled1 locationNCT07008378
Recruiting
Phase 3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)156 enrolled22 locationsNCT04047628
Recruiting
Phase 2

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Multiple Sclerosis
Eli Lilly and Company200 enrolled50 locationsNCT06220669
Recruiting

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

Movement DisordersAmyotrophic Lateral SclerosisDegenerative Disorder+1 more
Target ALS Foundation, Inc.1,000 enrolled12 locationsNCT05137665